Caffeine
Sold as Cayona, Cafcit, Antisom, Wide awake, Universal concentration, Lert, Regmakers, Focus
1,3,7-Trimethylpurine-2,6-dione
Drag to rotate. Structure from PubChem CID 2519.
Background
Registration
- Applicants
- 7
- Registrations
- 8
- Schedule source
- SAHPRA documentation
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Safeline Pharmaceuticals (Pty) Ltd | Cayona | 20 mg/ml | 480091 | Not determined | None |
| Equity Pharmaceutical (Pty) LtdCertificate held by Equity Pharmaceuticals (Pty) Ltd | Cafcit | 5 mg | 560312 | S3 | PIPIL |
| The Premier Pharmaceutical Co LtdCancelled | Antisom, Focus | tablets | B0525, B1434 | Not determined | None |
| A & E Pharmaceuticals (Pty) LtdCancelled | Wide awake | Not stated | B0766 | Not determined | None |
| Universal Pharmaceuticals (Pty) Ltd | Universal concentration | tablets | B0842 | Not determined | None |
| Lebasi Pharmaceuticals (Pty) Ltd | Lert | tablets | B0848 | Not determined | None |
| Adcock ingram limited | Regmakers | tablets | B0955 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Cayona 20 mg/ml EACH 1,0 ml SOLUTION CONTAINS CAFFEINE CITRATE EQUIVALENT TO CAFFEINE 10,0 mg | 20 mg/ml | 48009148/1.4/0091 | Registered | Not determined | None |
| Cafcit EACH 1,0 ml SOLUTION CONTAINS CAFFEINE CITRATE EQUIVALENT TO CAFFEINE 5,0 mg | 5 mgSolution for iv infusion or oral administration. | 56031256/1.4/0312Approved 31 October 2023 | Registered | S3 | PIPIL |
| Antisom tablets TABLET CAFFEINE A 100 MG | Tablets | B0525 | Cancelled | Not determined | None |
| Wide awake TABLETCAFFEINE A 100 MGCAFFEINE CITRATE A 100 mg | Not listed | B0766 | Cancelled | Not determined | None |
| Universal concentration tablets TABLET CAFFEINE A 120 MG | Tablets | B0842 | Old Medicine | Not determined | None |
| Lert tablets EACH TABLET CONTAINS CAFFEINE A 90 mg CAFFEINE CITRATE A 90 mg | Tablets | B0848 | Old Medicine | Not determined | None |
| Regmakers tablets EACH TABLET CONTAINS CAFFEINE A 150 mg | Tablets | B0955 | Old Medicine | Not determined | None |
| Focus CAPSULE CAFFEINE A 250 MG | Not listed | B1434 | Cancelled | Not determined | None |
Regulatory status
Where S3 sits on the scale
Needs a doctor's prescription, dispensed by a pharmacist.
Schedule 3 medicines can only be sold on a prescription from an authorised prescriber, such as a doctor or dentist. A pharmacist dispenses the medicine once they have the written prescription, or a verbal instruction from a prescriber they know. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S3, read from the product's PI-PIL leaflet.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Caffeine citrate equivalent to caffeine
S3: Caffeine
- when intended for injection.
Consolidated Schedules 06 July 2026, line 3256
Pharmacological class: Respiratory stimulants. (class 1.4)
1 of 10 approved products with this ingredient carry S5 on their leaflet.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
Schedule Verification
Cafcit, Equity Pharmaceutical (Pty) Ltd is scheduled S3 in its official SAHPRA documents, read with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.